title: Immunotherapy for acute myeloid leukemia.
abstract: Immunotherapeutic strategies have become part of standard cancer treatment. Chimeric and humanized antibodies have demonstrated activity against a variety of tumors. Although the humanized anti-CD33 antibody HuM195 has only modest activity against overt acute myeloid leukemia (AML), it can eliminate minimal residual disease in acute promyelocytic leukemia. High-dose radioimmunotherapy with b-particle-emitting isotopes targeting CD33, CD45, and CD66 can potentially allow intensification of antileukemic therapy before hematopoietic stem cell transplantation. Conversely, a-particle immunotherapy with isotopes such as bismuth-213 or actinium-225 offers the possibility of selective tumor cell kill while sparing surrounding normal tissues. Targeted chemotherapy with the anti-CD33- calicheamicin construct gemtuzumab ozogamicin has produced remissions in relapsed AML and appears promising when used in combination with standard chemotherapy for newly diagnosed AML. T-cell recognition of peptide antigens presented on the cell surface in combination with major histocompatibility complex antigen provides another potentially promising approach for the treatment of AML.
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, Box 458, New York, NY 10021, USA. jurcicj@mskcc.org
authors.forename: Joseph G
authors.initials: JG
authors.lastname: Jurcic
mesh_terms: D000617:Aminoglycosides / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000737:chemistry; D015214:Antigens, Differentiation, Myelomonocytic / Q000737:chemistry; D001729:Bismuth / Q000737:chemistry; D015815:Cell Adhesion Molecules / Q000737:chemistry; D000079982:Gemtuzumab; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000922:Immunotoxins / Q000737:chemistry; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D017493:Leukocyte Common Antigens / Q000737:chemistry; D016499:Radioimmunotherapy; D011868:Radioisotopes / Q000737:chemistry; D012008:Recurrence; D012074:Remission Induction; D063268:Sialic Acid Binding Ig-like Lectin 3; D013601:T-Lymphocytes / Q000378:metabolism
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; C069847:CD66 antigens; D015815:Cell Adhesion Molecules; D000922:Immunotoxins; D011868:Radioisotopes; D063268:Sialic Acid Binding Ig-like Lectin 3; D000079982:Gemtuzumab; D017493:Leukocyte Common Antigens; D001729:Bismuth